FDA approves first quadrivalent intradermal influenza vaccine
the ONA take:
Sanofi Pasteur has announced that the U.S. Food and Drug Administration (FDA) has approved Fluzone Intradermal Quadrivalent vaccine. A trivalent formulation of the vaccine has been available for 3 years, but the quadrivalent formulation will help to protect against four strains of influenza rather than three.
The vaccine is approved for adults aged 18 to 64 years for the prevention of infection by influenza A and B subtypes. The trivalent vaccine protects against two influenza A subtypes and only one influenza B subtype, but it is influenza B that is a common cause of morbidity and morality associated with influenza.
The most common adverse effects observed in clinical trials were erythema, headache, induration at the injection site, malaise, myalgia, pain, pruritus, and swelling. These reactions typically occurred within 3 days of vaccination and were mild to moderate in severity.
In addition, the intradermal vaccines is equally as effective as an intramuscular flu shot. Like other flu shots, the Fluzone Intradermal Quadrivalent vaccine should not be administered to patients with egg allergies or to anyone who has experienced a hypersensitivity reaction to a previous influenza vaccine.
The FDA has approved Fluzone Intradermal Quadrivalent vaccine for influenza.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|